Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
New deal strengthens Congenica’s presence in India
AI-driven company anumana partnered with Novartis to drive the development of its electrocardiogram (ECG) AI algorithms to detect subclinical heart disease.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
The hospital will use the bus to reach out to people with eye ailments through their various eye camps, diagnosing and treating them wherever possible.
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
Subscribe To Our Newsletter & Stay Updated
